Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection
  • Noel Lorenzo-Villalba
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Yasmine Maouche
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Aneska Syrovatkova
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Felix Pham
    Service de Dermatologie, Hôpitaux Universitaires de Strasboug, Strasbourg, France
  • Jean-Baptiste Chahbazian
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Pierre Pertoldi
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  • Emmanuel Andrès
    Service de Médecine Interne, Diabète et Maladies Métaboliques. Hôpitaux Universitaires de Strasboug. France
  • Abrar-Ahmad Zulfiqar
    Service de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Keywords

COVID-19, dissecting haematoma, dermatoporosis, coagulation abnormalities

Abstract

We describe the case of a patient hospitalized for acute decompensated heart failure in a standard medical ward. During hospitalization, he was diagnosed with COVID-19 and transferred to a special unit. The clinical course was marked by worsening of the respiratory disease, the development of right parotiditis and thrombosis of the left internal jugular vein. Therapeutic anticoagulation was initiated and 2 days later, the minimal dermatoporosis lesions previously present in the upper extremities evolved to haemorrhagic bullae with intra-bullae blood clots and dissecting haematomas. Surgical management of the dissecting haematomas was difficult in the context of haemostasis abnormalities. The patient died 29 days after hospital admission.

VIEW THE ENTIRE ARTICLE

References

  • Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J, Tammaro A, et al. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol 2020 Apr 24. doi: 10.1111/jdv.16530 [Epub ahead of print].

  • Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34(5):e212–e213.

  • Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020:S0735-1097(20)35008-7.

  • Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010;21:459–463.

  • Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382(17):e38.

  • Wang T, Chen R, Liu C, Liang W, Gaun W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7(5):e362–e363.

  • Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology 2007;215(4):284–294.
  • Views: 1067
    HTML downloads: 122
    PDF downloads: 742


    Published: 2020-06-12
    Issue: 2020: Vol 7 No 7 (view)


    How to cite:
    1.
    Lorenzo-Villalba N, Maouche Y, Syrovatkova A, Pham F, Chahbazian J-B, Pertoldi P, Andrès E, Zulfiqar A-A. Cutaneous Complications Secondary to Haemostasis Abnormalities in COVID-19 Infection. EJCRIM 2020;7 doi:10.12890/2020_001769.

    Most read articles by the same author(s)

    1 2 > >>